NHTA is a proud ENCePP partner conducting PASS and regulatory-RWE studies with Nordic data. With deep scientific expertise, we help elevate the visibility of real-world evidence in regulatory decision-making.
Insights
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)
Did you know that NHTA is a proud partner of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), coordinated by the European Medicines Agency (EMA)?
At NHTA, we conduct Post-Authorisation Safety Studies (PASS) as part of the ENCePP initiative. Are you seeking a reliable partner with unparalleled scientific expertise to execute robust and compliant PASS and regulatory-RWE studies?
As a key advancement, the EU PAS Register® has been replaced by the Catalogue of Real-World Data (RWD) Studies, offering greater transparency for non-interventional post-authorisation studies and RWD-based research. This marks a significant step forward in elevating the credibility and visibility of RWD in the regulatory landscape.
Contact Johanna Simin, PhD MSc, at js@nhta.com or connect with our RWE experts at NHTA to explore how Nordic data can be utilised in regulatory processes.
